Yahoo Malaysia Web Search

Sign In

Search results

  1. www.regeneron.comRegeneron Pharmaceuticals: Delivering Life-transforming Medicines

    At Regeneron, we've been committed to making a difference in patients' lives for over 30 years. We've done this by following the science. One of the things that's made Regeneron really unique is its willingness to invest in cutting edge technologies.

  2. en.wikipedia.org › wiki › Regeneron_PharmaceuticalsRegeneron Pharmaceuticals - Wikipedia

    Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

  3. www.regeneron.com › globalRegeneron Pharmaceuticals: Delivering Life-transforming Medicines

    Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.

  4. www.regeneron.com › aboutAbout Regeneron Pharmaceuticals: Innovative Biotechnology

    At Regeneron, we move science to medicine because our world is meant for more. Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

  5. www.regeneron.com › locationsOur Locations Across the Globe | Regeneron

    Find addresses and contact information for Regeneron's offices in North America, Europe and Asia. Our antibody combination is not currently authorized for use in any U.S. region. Please refer to the authorized Fact Sheet and FDA statement for additional details.

  6. investor.regeneron.com › press-releasesPress Releases | Regeneron Pharmaceuticals Inc.

    May 31. Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation. May 23. Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO. May 20.

  7. newsroom.regeneron.com › news-releases › news-release-detailsINVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.

    Jul 30, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab). The authorization now includes post-exposure prophylaxis in people at high risk for progression ...